OKYO Pharma Ltd — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2022. This is an annual report, not a standalone 2021 Q4 filing. Financial statements are audited and prepared under IFRS as issued by the IASB, in U.S. dollars; the company’s functional currency is pound sterling.
Business context
OKYO is a pre-revenue, preclinical biopharmaceutical company developing therapies for inflammatory eye disease and ocular pain. Its lead candidate, OK-101, is being developed primarily for dry-eye disease (DED); OK-201 remains at an exploratory stage. Neither candidate had entered human trials by the reporting date, and no product had regulatory approval.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.301 million | $0.174 million |
| General and administrative expense | $4.916 million | $3.192 million |
| Total operating expenses | $6.218 million | $3.366 million |
| Net loss | $5.431 million | $3.354 million |
| Total comprehensive loss | $6.268 million | $3.007 million |
| Net cash used in operating activities | $5.468 million | $1.600 million |
| Cash and cash equivalents at year-end | $2.701 million | $6.889 million |
| Working capital | $2.942 million | $5.279 million |
| Total liabilities | $1.353 million | $1.772 million |
Margins are not meaningful because the company had no product revenue. FY2022 operating cash use increased as development activity resumed and advanced. The company reported no borrowings at March 31, 2022; convertible notes had been converted into shares. Operating lease commitments were approximately $19,000, due within one year.
Liquidity note: The balance sheet reports current assets of $4.295 million and current liabilities of $1.353 million, implying working capital of $2.942 million. A risk-factor passage instead states working capital was approximately $6.9 million; the filing does not reconcile this inconsistency.
Changes versus the prior year
- Operating expenses rose $2.851 million, with R&D expense increasing by $1.127 million as activity on OK-101 advanced, and G&A increasing by $1.724 million amid expanded management and company activity.
- Net loss increased $2.078 million. The tax credit rose to $0.787 million from $0.025 million, partly offsetting the higher expenses.
- Operating cash outflow rose $3.868 million. Cash declined by $4.189 million during FY2022, despite $2.153 million of financing cash inflow and $0.837 million of adverse currency translation in comprehensive income.
- Ordinary shares outstanding increased from 672.8 million to 1.374 billion, primarily through warrant exercises and conversion of convertible notes, substantially diluting existing shareholders.
Outlook, commentary and principal risks
- Management stated it was on track to submit an IND for OK-101 for DED in Q4 2022. Following FDA pre-IND discussions, the company planned a first human study as a Phase 2 safety and efficacy trial, rather than a standard Phase 1 study, targeting approximately 200–250 patients and an expected 6–8 months from first enrollment. These are plans, not completed milestones.
- Preclinical results described for OK-101—including DED and ocular-pain findings—were from laboratory or animal models. The filing cautions that such findings may not translate to human safety or efficacy. OK-201 showed encouraging mouse-model results but was deprioritized.
- The auditor issued an unmodified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. Management projected cash exhaustion around October 2022 without further financing. An August 2022 related-party credit facility of $2 million, at 16% annual interest and repayable six months after drawdown, was expected to extend liquidity to approximately April 2023; it does not fund the full clinical program.
- After year-end, the company raised $2.5 million gross in a May 2022 ADS offering, before discounts and expenses. Management expected to seek further funding; additional equity could be dilutive, and other financing or partnering could require concessions.
- Key risks include clinical and regulatory failure, dependence on OK-101 and third parties, competition, intellectual-property challenges, future financing needs, and potential trial, supply-chain or development delays. The filing also identifies COVID-19-related operational risks.
- Management reported ineffective disclosure controls and a material weakness in internal control over financial reporting due to limited accounting resources and corrected audit-phase misstatements. It described hiring additional resources and implementing review controls, but remediation was not yet established as complete.
Investor verification priorities
- Confirm current cash, whether the $2 million related-party facility was drawn, its repayment terms, and subsequent financing and runway.
- Reconcile the stated $6.9 million working-capital figure with the audited balance sheet’s $2.942 million calculation.
- Check the actual timing and outcome of the OK-101 IND submission and FDA review, and whether the planned Phase 2 design and timetable proceeded.
- Assess the clinical rationale and regulatory basis for proceeding directly to Phase 2, given the absence of human safety data and the preclinical-only evidence.
- Review subsequent share issuance, warrants, options and financing terms to gauge dilution and related-party exposure.
- Check progress in remediating the disclosed internal-control weakness and any later auditor or financial-reporting developments.